论文部分内容阅读
目的：探讨大肠癌患者多药耐药与组织学分级和临床病理学Ｄｕｋｅｓ分期之间的关系。方法：采用逆转录－聚合酶链反应（ＲＴ－ＰＣＲ）的方法检测了６０例大肠癌患者肿瘤组织的ｍｄｒ－１表达水平，同时检测了其中２０例大肠癌患者的正常大肠组织作为对照。结果：高、中、低分化大肠癌组织之间ｍｄｒ－１表达水平具有极显著差异，大肠癌组织和正常大肠组织之间ｍｄｒ－１表达水平具有极显著差异，Ｄｕｋｅｓ分期的不同期之间ｍｄｒ－１表达水平无显著差异。结论：临床检测大肠癌患者ｍｄｒ－１基因的表达，可以预测患者对化疗的敏感性，从而进行有针对性的治疗，使化疗个体化。
Objective: To investigate the relationship between multidrug resistance and histological grade and clinical pathology Dukes stage in patients with colorectal cancer. Methods: The expression of mdr-1 in 60 cases of colorectal cancer was detected by reverse transcription-polymerase chain reaction (RT-PCR). The normal colorectal tissues of 20 patients with colorectal cancer were detected as controls. RESULTS: The expression of mdr-1 was significantly different between high, moderate and poorly differentiated colorectal cancer tissues. The expression level of mdr-1 was significantly different between colorectal cancer tissues and normal colorectal tissues. The difference between different stages of Dukes stage was mdr. There was no significant difference in the expression level of -1. Conclusion: Clinical detection of mdr-1 gene expression in patients with colorectal cancer can predict the sensitivity of patients to chemotherapy, and thus targeted treatment, individualized chemotherapy.